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Globally there is an alarming increase in the incidence of type 2 
diabetes mellitus (DM) and obesity. South Africa (SA) is now regarded 
as one of the world’s most obese nations.[1] Pregnancy is characterised 
by insulin resistance and hyperinsulinaemia, predisposing some 
women to develop gestational DM (GDM). It is well recognised that 
women who develop GDM in pregnancy are at an increased risk 
of pregnancy complications as well as DM in later life. In addition, 
poor glycaemic control in pregnancy impacts adversely on neonatal 
outcome and puts the child at increased risk of developing obesity 
and DM.[2]
Over the decades, global organisations have recommended a 
plethora of algorithms for the screening and diagnosis of GDM. In 
2010, the International Association of Diabetes in Pregnancy Study 
Groups (IADPSG) proposed consensus-derived cut-off values for 
the diagnosis of GDM. Their thresholds were derived from the 
1.75 increase in odds of having a complication in pregnancy based 
on the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) 
study population. The IADPSG criteria have now been adopted 
by the International Federation of Gynecology and Obstetrics and 
most international organisations, with the American Congress of 
Obstetricians and Gynecologists and the National Institute for Health 
and Care Excellence (NICE) being notable exceptions.[3]
The prevalence of GDM in SA is estimated to be 1.6 - 8.8% based on 
scant data and selective risk factor-based screening.[4] While it is well 
known that women with GDM have certain definable risk factors, 
there is concern that a significant proportion of women with GDM 
will be missed if screened by risk factors alone, as has been illustrated 
in numerous studies.[5-7] Current international opinion favours the 
universal screening of all pregnant women for GDM, where local 
circumstances allow.
Screening for and diagnosis of GDM in SA remain disorderly. 
There are disparities in protocols between provinces and hospitals. 
In 2012, the Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA) recommended risk factor-based selective 
screening at 24 - 28 weeks’ gestation using the World Health 
Organization (WHO) 1999 criteria.[8] Risk factors include advanced 
maternal age, obesity, a family history of DM, previous adverse 
pregnancy outcome (congenital abnormality, recurrent miscarriages, 
delivery of a stillborn child), delivery of a macrosomic baby in a 
previous pregnancy, certain ethnic backgrounds, or significant or 
persistent glycosuria. The society’s new guidelines will recommend 
universal screening, according to which all pregnant women will 
be screened for GDM with the IADPSG criteria (Z Bayat, personal 
communication, September 2016). At present, risk factor-based 
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selective screening is the predominant practice in SA. The most 
commonly used diagnostic criteria in SA are the NICE, IADPSG and 
WHO 1999 criteria. However, each centre has decided independently 
on which diagnostic criteria to use. In Pretoria, the IADPSG criteria[3] 
are used, Johannesburg uses the NICE criteria,[3] while the Western 
Cape Province uses a combination of the Western Cape criteria[9] 
and the NICE guidelines.[3] The variation in diagnostic criteria used 
results in discrepancies in prevalence and the women classified as 
having GDM. This results in many women with GDM not receiving 
appropriate treatment.
Objectives
To determine the prevalence of GDM in an SA population. We 
compared the prevalence of GDM using the various diagnostic 
criteria, and also evaluated the risk factors associated with GDM.
Methods
This research was part of a larger study investigating screening 
strategies for GDM in an SA population. We carried out a prospective 
cohort observational study at a level 1 clinic in Johannesburg. One 
thousand pregnant women at <26 weeks’ gestation were recruited. 
Patients known to have GDM and those who were ≥26 weeks 
pregnant were excluded. Gestational age was based on the patient’s 
last normal menstrual period, an ultrasound scan or palpation of the 
symphysis-fundal height.
At recruitment, the women completed a questionnaire including 
demographic data and an evaluation of risk factors for GDM. A 
random glucose test was done and the glycated haemoglobin (HbA1c) 
level measured. If the random glucose level was >11.1 mmol/L or the 
HbA1c level >6.5%, the patient was referred to the local hospital for 
further management of DM. Otherwise, a 75 g 2-hour oral glucose 
tolerance test (OGTT) was scheduled for between 24 and 28 weeks’ 
gestation. At the time of the OGTT, HbA1c was measured again. All 
blood was drawn by a registered nurse and stored on ice until it was 
delivered to the laboratory on the same day.
The diagnosis of GDM was compared using the diagnostic criteria 
set out in Table 1.
Statistical analysis
The data were analysed using the Stata 13 statistical package 
(StataCorp, USA). Descriptive statistics were used to describe the 
population. Student’s t-test was calculated for continuous variables 
and the χ2 test for categorical data. The presence of any one risk 
factor was considered a positive finding. Risk factors considered were 
obesity (body mass index (BMI) ≥30 kg/m2), age ≥35 years, delivery 
of a baby weighing ≥4 000 g in a previous pregnancy, glycosuria, a 
history of GDM in a previous pregnancy, or a history of a baby with 
a congenital abnormality, an unexplained stillbirth, or recurrent 
pregnancy losses. The sensitivity and specificity for having at least 
one risk factor as a screening tool for GDM was calculated. The 
statistical significance level and the confidence interval were set at 
p<0.05 and 95%, respectively.
Ethics approval
Approval for the study was obtained from the Faculty of Health 
Sciences Ethics Committee, University of Pretoria (ref. no. 180/2012). 
Written informed consent was obtained from each patient prior 
to enrolment into the study. Participants were provided with an 
information leaflet on gestational diabetes.
Results
One thousand pregnant women were recruited. Eighty-two women 
(8.2%) had fetal losses and did not continue with the study, 163 
(16.3%) moved away from the area and were therefore lost to follow-
up, 194 (19.4%) were unreachable and 7 (0.7%) withdrew consent. 
Five hundred and fifty-four women (55.4%) therefore had complete 
data available for analysis.
The clinical and biochemical characteristics of the women with 
and without GDM based on the IADPSG criteria are given in Table 2. 
The mean age, weight, BMI, HbA1c level at recruitment and random 
glucose level at recruitment were significantly higher in women with 
GDM compared with those without.
All the women would have had an OGTT if universal screening had 
been employed, and only 254 (45.8%) would have had one if selective 
risk factor-based screening had been employed. The prevalence 
of GDM based on the different diagnostic criteria is illustrated in 
Figs  1 and 2. The prevalence was 25.8% with universal screening and 
15.2% with selective screening when the IADPSG criteria were used. 
Table 1. Diagnostic criteria for GDM commonly used in SA
Glucose 
level 
(mmol/L) IADPSG NICE
WHO 
1999 Western Cape
0 h 5.1 5.6 7.0 Random glucose 8 - 11 
mmol/L → fasting glucose
Fasting glucose ≥6 mmol/L 
→ for glucose profile
1 h 10 n/a n/a
2 h 8.5 7.8 7.8
GDM = gestational diabetes mellitus; SA = South Africa; IADPSG = International 
Association of Diabetes in Pregnancy Study Groups; NICE = National Institute for Health 
and Care Excellence; WHO = World Health Organization; n/a = not applicable.
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Fig. 1. Prevalence of GDM based on universal screening. (IADPSG = Inter­
national Association of Diabetes in Pregnancy Study Groups; NICE = 
National Institute for Health and Care Excellence; WHO = World Health 
Organization; W Cape = Western Cape.)
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Fig. 2. Prevalence of GDM based on selective screening. (IADPSG = Inter­
national Association of Diabetes in Pregnancy Study Groups; NICE = 
National Institute for Health and Care Excellence; WHO = World Health 
Organization; W Cape = Western Cape.)
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If we used the NICE criteria and universal screening the prevalence 
was 17.0%. If selective screening was used, the prevalence was 3.6%. 
With the WHO 1999 criteria, the prevalence of GDM was 7.2% 
with universal screening and 3.6% with selective screening. The 
Western Cape criteria would have diagnosed no woman in our study 
population as having GDM.
Table 3 illustrates the differences between patients who had GDM 
based on either the IADPSG criteria or the NICE criteria. There were 
significant differences in age, weight, BMI, HbA1c at booking and at 
the time of the OGTT, random and fasting glucose, and the number 
of patients with at least one risk factor for GDM.
In our study, 254 patients (45.8%) had at least one risk factor for 
GDM. Of these, 26.0% had GDM. However, the presence of one 
or more risk factors had a poor sensitivity (58.7%) and specificity 
(58.6%) for the detection of GDM in our study population (Table 4). 
The positive likelihood ratio was 1.42 and the negative likelihood 
ratio 0.704. Risk factors had a positive predictive value of 33.1%, a 
negative predictive value of 80.3% and an odds ratio of 2.02.
Discussion
The objective of this study was to determine the prevalence of 
GDM and its associated risk factors in an SA population. To our 
Table 2. Clinical and biochemical characteristics of subjects stratified by GDM based on IADPSG criteria
Variable No GDM (N=411) GDM (N=143) p-value
Age (yr), mean (range) 26.8 (15 - 42) 28.4 (13 - 42) 0.004
Weight (kg), mean (range) 68.5 (42.9 - 124) 72.1 (45.3 - 122.2) 0.010
Height (m), mean (range) 1.65 (14.8 - 46.2) 1.62 (1.47 - 1.78) 0.590
BMI (kg/m2), mean (range) 26.1 (1.45 - 1.82) 27.9 (17.5 - 47.2) 0.001
MUAC (cm), mean (range) 28.5 (18 - 42) 29.8 (17 - 45) 0.003
Parity, mean (range) 1.05 (0 - 4) 1.2 (0 - 5) 0.096
Hb (g/dL), mean (range) 12.3 (6.1 - 17.2) 12.5 (7.5 - 16.1) 0.370
HbA1c (%), mean (range)
Booking 5.1 (3.8 - 6.3) 5.3 (4.1 - 6.5) 0.001
OGTT 5.1 (4.0 - 7.7) 5.6 (4.4 - 6.4) 0.027
Random glucose (mmol/L), mean (range)
Capillary 4.6 (2.3 - 8.6) 4.7 (2.8 - 9.0) 0.565
Laboratory 4.5 (2.9 - 9.3) 4.7 (3.3 - 6.5) 0.002
Fasting glucose (mmol/L), mean (range)
Capillary 4.3 (2.8 - 6.3) 4.6 (2.7 - 8.4) 0.000
Laboratory 4.4 (2.1 - 4.9) 5.8 (3.9 - 13.4) 0.000
OGTT, 1-hour glucose (mmol/L), mean (range)
Capillary 6.4 (2.6 - 12.9) 7.0 (3.6 - 11.2) 0.000
Laboratory 5.6 (1.7 - 9.9) 6.7 (3.9 - 12.1) 0.000
OGTT, 2-hour glucose (mmol/L), mean (range)
Capillary 5.8 (3.3 - 10.4) 6.4 (4.4 - 15.5) 0.000
Laboratory 5.2 (1.8 - 8.4) 6.5 (3.4 - 13.8) 0.000
HIV, n (%)
Negative 296 (72.0) 93 (65.0)
Positive 111 (27.0) 49 (34.3) 0.252
Unknown 4 (1.0) 1 (0.7)
Anaemia (Hb <11 g/dL), n (%) N=324 N=122
No 245 (75.6) 104 (85.2) 0.500
Yes 79 (24.4) 18 (14.8)
Hypertension (BP >135/85 mmHg), n (%)
No 311 (75.7) 94 (65.7) 0.210
Yes 100 (24.3) 49 (34.3)
Education, n (%) N=394 N=141
< grade 12 231 (58.6) 81 (57.4) 0.807
≥ grade 12 163 (41.4) 60 (42.6)
Employment, n (%) N=408 N=142
Unemployed 257 (63.0) 73 (51.4) 
Employed 144 (35.3) 64 (45.1) 0.037
Scholar 7 (1.7) 5 (3.5)
Risk factors, n (%)
0 241 (58.6) 59 (41.3) 0.000
≥1 (n=254) 170 (41.4) 84 (58.7) 0.000
GDM = gestational diabetes mellitus; IADPSG = International Association of Diabetes in Pregnancy Study Groups; BMI = body mass index; MUAC = mid-upper arm circumference;  
Hb = haemoglobin; HbA1c = glycated haemoglobin; OGTT = oral glucose tolerance test; BP = blood pressure.
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knowledge, this is the first study to evaluate the IADPSG criteria in 
an SA population.
Screening for GDM in SA is chaotic. In 2012, SEMDSA 
recommended risk factor-based selective screening using the WHO 
1999 criteria.[8] The society’s new guidelines recommend universal 
screening with the IADPSG criteria (personal communication). This 
change in recommendation would translate to a >100% increase in 
the number of pregnant women who would need to be screened, and 
a 7.2-fold increase in the prevalence of GDM from 3.6% to 25.8%.
The incidence of GDM is increasing worldwide. The IADPSG diag-
nostic criteria were extrapolated from the population screened 
in the HAPO study. Although there was no clear inflection point 
above which the adverse effects of GDM increased, the IADPSG 
recommends diagnostic criteria based on an odds ratio of 1.75. [3,10] 
When these criteria were applied to the HAPO population, a GDM 
prevalence of 18% was found. However, a GDM prevalence of 25.8% 
was found in our study population when the IADPSG criteria were 
used. This markedly increased prevalence of GDM found with 
the IADPAG criteria is greater than the prevalence found in other 
countries.[3]
The significant increase in the prevalence of GDM reported in 
this study compared with previous SA studies can be attributed to 
the lower diagnostic threshold and the use of universal screening.[4] 
The IADPSG criteria were used because they are now recommended 
in an attempt to standardise the diagnosis of GDM globally[3] and are 
recommended in the proposed SEMDSA guidelines.
Changes in lifestyle in SA have contributed to the increasing risk 
of obesity. While modifiable, these changes have contributed to the 
Table 3. Comparison of subjects with GDM based on IADPSG and NICE criteria
Variable IADPSG (N=143) NICE (N=94) p-value
Age (years), mean (range) 28.4 (13 - 42) 28.7 (13 - 42) 0.010
Weight (kg), mean(range) 72.1 (45.3 - 122.2) 75.5 (45.3 - 122.2) 0.030
Height (m), mean (range) 1.62 (1.47 - 1.78) 1.61 (1.47 - 1.76) 0.850
BMI (kg/m2), mean (range) 27.9 (17.5 - 47.2) 28.3 (17.5 - 47.2) 0.000
MUAC (cm), mean (range) 29.8 (17 - 45) 30.0 (20 - 45) 0.010
Parity, mean (range) 1.2 (0 - 5) 1.3 (0 - 5) 0.060
Hb (g/dL), mean (range) 12.5 (7.5-16.1) 12.5 (8.3 - 15.7) 0.570
HbA1c (%), mean (range)
Booking 5.3 (4.1 - 6.5) 5.3 (4.2 - 6.5) 0.000
OGTT 5.6 (4.4 - 6.8) 5.9 (4.4 - 6.8) 0.020
Random glucose (mmol/L), mean (range)
Capillary 4.7 (2.8 - 9.0) 4.7 (2.8 - 9.0) 0.750
Laboratory 4.7 (3.3 - 6.5) 4.7 (3.3 - 9.3) 0.000
Fasting glucose (mmol/L), mean (range)
Capillary 4.6 (2.7 - 8.4) 4.6 (2.7 - 8.4) 0.000
Laboratory 5.8 (3.9 - 13.4) 6.0 (3.9 - 13.4) 0.000
HIV, n (%) N=103
Negative 93 (65.0) 66 (70.2) 
Positive 49 (34.3) 28 (29.8) 0.080
Unknown 1 (0.7) 0 (0)
Anaemia (Hb <11 g/dL), n (%) N=122 N=75
No 104 (85.2) 65 (86.7) 0.080
Yes 18 (14.8) 10 (13.3)
Hypertension (BP >135/85 mmHg), n (%)
No 94 (65.7) 61 (64.9) 0.060
Yes 49 (34.3) 33 (35.1)
Education, n (%) N=141 N=93
< grade 12 81 (57.4) 53 (57.0) 0.210
≥ grade 12 60 (42.6) 40 (43.0)
Employment, n (%) N=142 N=93
Unemployed 73 (51.4) 53 (57.0) 0.080
Employed 64 (45.1) 36 (38.7)
Scholar 5 (3.5) 4 (4.3)
Risk factors, n (%)
0 59 (41.3) 39 (41.5) 0.000
≥1 84 (58.7) 55 (58.5)
GDM = gestational diabetes mellitus; IADPSG = International Association of Diabetes in Pregnancy Study Groups; NICE = National Institute for Health and Care Excellence;  
BMI = body mass index; MUAC = mid-upper arm circumference; Hb = haemoglobin; HbA1c = glycated haemoglobin; OGTT = oral glucose tolerance test; BP = blood pressure.
Table 4. Performance of risk factors as a screening tool for GDM
Risk factors ≥1
TotalYes No
GDM, n (%)
Yes 84 (15.2) 59 (10.6) 143 (25.8)
No 170 (30.7) 241 (43.5) 411 (74.2)
Total, n (%) 254 (45.8) 300 (54.2) 554 (100)
GDM = gestational diabetes mellitus.
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increasing prevalence of DM in the general population.[1] Similarly, 
obesity is also associated with an increased likelihood of having 
GDM. It is known that women with GDM are at an almost 50% 
increased risk of developing DM within 10 years. The increasing 
incidence of GDM is of concern, as these women and their offspring 
are at an increased risk of cardiometabolic disease. It has also been 
demonstrated that the partners of women with GDM are at increased 
risk of developing type 2 DM.[11,12] There is a need for large-scale 
awareness and lifestyle modification programmes to alter these risks.
Currently the most widely used criteria for screening for GDM 
in SA are the NICE guidelines. The NICE criteria appear to be an 
attractive alternative for the diagnosis of GDM. Their use in this 
study resulted in a 17.0% prevalence of GDM. However, this may 
not be ideal. Meek et al.[13] have found that women who did not 
have GDM if the NICE criteria were applied but had GDM if the 
IADPSG criteria were used were still at an increased risk of adverse 
obstetric outcomes such as an increased caesarean section rate, 
polyhydramnios and fetal macrosomia.
Risk factor-based screening has been widely utilised to identify 
women at high risk of having GDM. If we had used selective 
screening in our study, 59 patients (10.6%) with GDM would not have 
been diagnosed if we had used the IADPSG diagnostic criteria, and 
39 (7.0%) if we had used the NICE diagnostic criteria.
Historically risk factor-based selective screening has been 
recommended for screening for GDM, as it was not considered to 
be cost-effective to subject all women to laboratory testing. Risk 
factor-based screening performs poorly as a screening tool for GDM. 
It has also been found to have poor sensitivity and specificity in other 
studies.[14,15] Furthermore, a major challenge of selective screening 
is that it places a high demand on the healthcare worker to identify 
patients who should be screened. In effect, this results in reduced 
compliance and inadequate screening and testing.
Universal screening and the low diagnostic threshold proposed 
by the IADPSG, on the other hand, may have the potential to over-
diagnose GDM. This has both financial and workload implications, 
which have been the subject of much debate.[16]
The Western Cape guidelines propose a novel approach to screening 
for GDM. In our study, no patients were diagnosed with GDM when 
these criteria were applied. This may be due to the low socioeconomic 
status of the population in which this study was conducted. Because 
of poor social circumstances, many pregnant women present to the 
antenatal clinic without having eaten an adequate breakfast, as can be 
seen by the similar random and fasting glucose measurements.
Selective screening remains an alluring option for SA. In addition 
to being a middle- to low-income country, we are faced with a 
dual burden of disease – malnutrition, poverty and communicable 
diseases, while obesity and lifestyle-related non-communicable 
diseases are increasing. However, if we are to consider risk factor-
based screening, we would have to define appropriate, simply applied 
risk factors and evaluate the efficacy of such a strategy.
Study strengths and limitations
The strengths of this study were that we prospectively assessed the 
prevalence of GDM and its associated risk factors in a low-risk SA 
population, and that we applied universal screening and the IADPSG 
criteria. The limitations are that this was a local study in a black 
African population and there was a large loss to follow-up.
Conclusions
Universal screening is the only strategy by which the majority of 
women with GDM will be diagnosed. There will be a substantial 
increase in the prevalence of GDM in SA with the use of the IADPSG 
criteria, regardless of whether universal or selective screening is 
implemented. We need to investigate and standardise the ideal 
strategy for screening for GDM in the SA context. Owing to the varied 
health priorities in this country, it is evident that an appropriate set of 
diagnostic criteria needs to evolve from a consensus approach based 
on balancing obstetric and long-term health risks and benefits in our 
unique socioeconomic and clinical context.
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